Blog
RSS FeedPosted by Michael Wonder on 01 Dec 2022
Reimbursed access to Bylvay (odevixibat) approved in France for patients with PFIC 1 & 2
30 November 2022 - Albireo Pharma today announced that the Committee Economic Health Products has approved reimbursed access to Bylvay (odevixibat) ...
Posted by Michael Wonder on 26 Apr 2022
HAS decides in favour of reimbursement of Paxlovid
25 April 2022 - After authorising early access to Paxlovid for the treatment of COVID-19 on January 22, HAS assessed ...
Posted by Michael Wonder on 21 Apr 2022
Hansa Biopharma granted added benefit ASMR 3 by French Transparency Commission for Idefirix (imlifidase) as desensitisation treatment for highly sensitised kidney transplant patients
20 April 2022 - The opinion by the Transparency Commission follows after Idefirix was granted a funded Early Access Program by ...
Posted by Michael Wonder on 30 Mar 2022
Cystic fibrosis: early access granted to the Kaftrio/Kalydeco combination
29 March 2022 - The High Authority for Health has authorised early access to a first treatment for children aged 6 ...
Posted by Michael Wonder on 17 Sep 2020
Transparency Commission publishes its opinion on Veklury
17 September 2020 - Gilead withdrew its request for the reimbursement of remdesivir in France on 31 August 2020. ...
Posted by Michael Wonder on 16 Dec 2018
Transparency Commission publishes its opinion for Kymriah
14 December 2018 - Opinion published following an examination of written submissions on 12 December 2018. ...
Posted by Michael Wonder on 09 Dec 2018
Transparency Commission publishes its opinion for Yescarta
7 December 2018 - Opinion published following an examination of written submissions on 5 December 2018. ...
Posted by Michael Wonder on 03 Oct 2018
Axumin (fluciclovine (18F)) receives positive recommendation from Transparency Committee of the French HAS for use in PET imaging of suspected recurrent prostate cancer
2 October 2018 - Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that the Transparency Committee of ...
Posted by Michael Wonder on 06 Jul 2017
HAS publishes TC opinion on Olumiant
6 July 2017 - The medical service rendered by Olumiant (baricitinib) is important. ...
Posted by Michael Wonder on 21 Jun 2017
Transparency Commission publishes opinion for Keytruda
20 June 2017 - The opinion relates to the use of pembrolizumab for the first-line use in patients with non-small-cell ...
Posted by Michael Wonder on 25 May 2017
Transparency Commission publishes its review of Keytruda's SMR & ASMR
22 May 2017 - The Transparency Commission has reviewed its SMR & ASMR ratings of pembrolizumab for malignant melanoma. ...
Posted by Michael Wonder on 15 May 2017
TC publishes opinion on Pfizer's Ibrance
11 May 2017 - The Commission considers that the medical service rendered by palbociclib when used in combination with letrozole ...
Posted by Michael Wonder on 12 Apr 2017
HAS publishes Transparency Commission opinion for Keytruda
12 April 2017 - The opinion relates the use of pembrolizumab by patients with non-small-cell lung cancer. ...
Posted by Michael Wonder on 22 Oct 2016
France's High Authority of Health is in favour of delisting Alzheimer's disease drugs
22 October 2016 - The Transparency Committee, responsible for evaluating medicinal products within the High Authority of Health recommended against ...
Posted by Michael Wonder on 27 Sep 2016
TC opinion on Lyxumia finally published
26 September 2016 - The Transparency Commission has published its opinion on Sanofi's GLP-1 analogue. ...